Pfizer and Blackstone Agree $1.5 Billion Co-Funding for Obesity Drug

what happened

Pfizer and Blackstone Life Sciences have announced a strategic co-funding agreement for an obesity program. Under the deal, funds managed by Blackstone will pay up to $1.5 billion of development costs for berobenatide through 2028. TradingView and Reuters reported the details, citing the companies' announcement.

In return, Blackstone is eligible for milestone payments. These depend on U.S. regulatory approval of monthly injectable dosing for chronic weight management and on certain commercial sales targets. Blackstone acquires no rights or ownership in the drug, and Pfizer retains full operational control of the program.

why it matters

For markets, the deal means Pfizer is bringing in outside capital for a large obesity program without stretching its own budget. Blackstone's payments are only triggered if the drug succeeds, so part of the financial risk shifts to the investor.

market impact

Pfizer shares: outside funding eases the cost burden of its obesity program.

tags

instruments

on polymarket